Revue des sciences de la santé

  • ISSN: 1108-7366
  • Indice h du journal: 51
  • Note de citation du journal: 10.69
  • Facteur d’impact du journal: 9.13
Indexé dans
  • Genamics JournalSeek
  • Infrastructure nationale des connaissances en Chine (CNKI)
  • CiteFactor
  • CINAHL complet
  • Scimago
  • Bibliothèque des revues électroniques
  • Répertoire d'indexation des revues de recherche (DRJI)
  • EMCare
  • OCLC - WorldCat
  • Commission des bourses universitaires
  • Fondation genevoise pour la formation et la recherche médicales
  • Pub européen
  • Google Scholar
  • SHERPA ROMÉO
  • Laboratoires secrets des moteurs de recherche
Partager cette page

Abstrait

Miglustat: A Glycotransferase Inhibitor for Covid-19 Treatment

Dean Tatlow

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) undergoes blood type specific glycosylation which has implications for infection susceptibility and replication without detection from the immune system. SARS-CoV-2 hijacks the host cell glycotransferase resulting in spike protein glycosylation resembling blood type antigens. Infection risk correlates to blood types that do not have anti-A and/or anti-B antibodies similar to that seen for ABO blood type recipients. The universal recipient AB is highly susceptible to infection lacking both anti-A and B antibodies, whereas blood type O has both antibodies resulting in less risk of infection. Once infected, SARS-CoV-2 obtains the blood type specific glycosylation of the host resulting in an effective camouflage against immune system recognition. Decoding the link between blood type and coronavirus disease 2019 (COVID-19) susceptibility exposes a role for miglustat a glycosyltransferase inhibitor in treatment. Use of the FDA-approved glycosyltransferase inhibitor miglustat can inhibit spike protein glycosylation revealing the SARS-CoV-2 virus for immune system recognition.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié